Hint mode is switched on Switch off
For swift navigation between sections

Qiagen
LEI 54930036WK3GMCN17Z57

PDF download

Choose all Reset all
Download Cancel
Organization name
Qiagen N.V.
Country name
Netherlands
Country of registration
Netherlands
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
1,276 mln USD
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding Qiagen N.V., the company operates more than 35 offices in over 20 countries. Qiagen’s shares are listed at the technology-focused U.S. stock exchange Nasdaq (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Peer M. Schatz is the company’s Chief Executive Officer. The main operative headquarters are located in Hilden, Germany (near Düsseldorf).

Awards

News

15/07/2026 QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
19/01/2026 QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast
16/12/2025 QIAGEN N.V. (NYSE:QGEN) Stock Analysis: A Closer Look at Growth Potential and Financial Health
13/10/2025 QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast
08/04/2025 QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
All organization news

Documentation

IFRS/US GAAP reports

2025
IV q eng
2024
IV q eng
2023
IV q eng
2022
IV q eng
2021
I q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
IV q eng
2016
IV q eng
2015
IV q eng
2014
IV q eng
Show more Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    54930036WK3GMCN17Z57
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001015820
Registration is required to get access.